Boston Scientific announces results for third quarter 2025

Core Insights - Boston Scientific Corporation reported net sales of $5.065 billion for Q3 2025, reflecting a growth of 20.3% on a reported basis, 19.4% operationally, and 15.3% organically compared to the previous year [1][6] - The company achieved a GAAP net income of $755 million, or $0.51 per share, up from $469 million, or $0.32 per share, in the prior year, with adjusted EPS of $0.75 compared to $0.63 a year ago [1][6] Financial Performance - The net sales growth by business segment included: - Endoscopy: 9.0% organic growth - Urology: 27.5% operational growth - Neuromodulation: 8.6% operational growth - MedSurg: 15.6% operational growth - Cardiology: 23.1% operational growth - Peripheral Interventions: 15.8% operational growth [4][6] - Regional net sales growth included: - U.S.: 27.0% reported growth - EMEA: 2.6% reported growth - APAC: 17.1% reported growth - LACA: 10.4% reported growth - Emerging Markets: 11.8% reported growth [4][6] Strategic Developments - The company announced the PMDA approval in Japan for expanded labeling of the FARAPULSE™ Pulsed Field Ablation System [6] - Enrollment commenced in the AGENT DCB STANCE trial to assess the AGENT™ Drug-Coated Balloon's safety and effectiveness [6] - Boston Scientific completed the acquisition of Elutia, Inc. for the EluPro™ BioEnvelope and CanGaroo® Envelope [6] - An agreement was reached to acquire Nalu Medical, Inc., which focuses on chronic pain relief through peripheral nerve stimulation [6] Guidance - For the full year 2025, the company estimates net sales growth of approximately 20% on a reported basis and 15.5% on an organic basis [7] - For Q4 2025, the estimated net sales growth is projected to be between 14.5% and 16.5% on a reported basis and 11% to 13% on an organic basis [8]